Aspirin desensitization
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/119316 |
Resumo: | Low-dose acetylsalicylic acid (ASA) is widely used during pregnancy to prevent obstetric complications of placental dysfunction, such as preeclampsia, stillbirth and fetal growth restriction, and obstetric complications in pregnant women with antiphospholipid syndrome. ASA-sensitive pregnant women cannot benefit from the effects of ASA due to the possibility of severe or potentially life-threatening hypersensitivity reactions to ASA. ASA desensitization is a valuable and safe therapeutic option for these women, allowing them to start daily prophylaxis with ASA and prevent pregnancy complications. The authors discuss the recent advances in obstetric conditions preventable by ASA and the management of ASA hypersensitivity in pregnancy, including ASA desensitization. To encourage the implementation of ASA desensitization protocols in ASA-sensitive pregnant women, they also propose a practical approach for use in daily clinical practice. |
id |
RCAP_93af7dd850ba7063b11420f72ede9301 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/119316 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Aspirin desensitizationImplications for acetylsalicylic acid-sensitive pregnant womenAntiphospholipid syndromeAspirinAspirin desensitizationFetal growth restrictionPreeclampsiaPregnancyMedicine(all)Low-dose acetylsalicylic acid (ASA) is widely used during pregnancy to prevent obstetric complications of placental dysfunction, such as preeclampsia, stillbirth and fetal growth restriction, and obstetric complications in pregnant women with antiphospholipid syndrome. ASA-sensitive pregnant women cannot benefit from the effects of ASA due to the possibility of severe or potentially life-threatening hypersensitivity reactions to ASA. ASA desensitization is a valuable and safe therapeutic option for these women, allowing them to start daily prophylaxis with ASA and prevent pregnancy complications. The authors discuss the recent advances in obstetric conditions preventable by ASA and the management of ASA hypersensitivity in pregnancy, including ASA desensitization. To encourage the implementation of ASA desensitization protocols in ASA-sensitive pregnant women, they also propose a practical approach for use in daily clinical practice.Comprehensive Health Research Centre (CHRC) - pólo NMSNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNBenito-Garcia, FilipePires, InêsLima, Jorge2021-06-15T22:21:09Z2021-042021-04-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/119316eng1010-660XPURE: 29781806https://doi.org/10.3390/medicina57040390info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:53:45Zoai:run.unl.pt:10362/119316Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:53:45Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Aspirin desensitization Implications for acetylsalicylic acid-sensitive pregnant women |
title |
Aspirin desensitization |
spellingShingle |
Aspirin desensitization Benito-Garcia, Filipe Antiphospholipid syndrome Aspirin Aspirin desensitization Fetal growth restriction Preeclampsia Pregnancy Medicine(all) |
title_short |
Aspirin desensitization |
title_full |
Aspirin desensitization |
title_fullStr |
Aspirin desensitization |
title_full_unstemmed |
Aspirin desensitization |
title_sort |
Aspirin desensitization |
author |
Benito-Garcia, Filipe |
author_facet |
Benito-Garcia, Filipe Pires, Inês Lima, Jorge |
author_role |
author |
author2 |
Pires, Inês Lima, Jorge |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Comprehensive Health Research Centre (CHRC) - pólo NMS NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
dc.contributor.author.fl_str_mv |
Benito-Garcia, Filipe Pires, Inês Lima, Jorge |
dc.subject.por.fl_str_mv |
Antiphospholipid syndrome Aspirin Aspirin desensitization Fetal growth restriction Preeclampsia Pregnancy Medicine(all) |
topic |
Antiphospholipid syndrome Aspirin Aspirin desensitization Fetal growth restriction Preeclampsia Pregnancy Medicine(all) |
description |
Low-dose acetylsalicylic acid (ASA) is widely used during pregnancy to prevent obstetric complications of placental dysfunction, such as preeclampsia, stillbirth and fetal growth restriction, and obstetric complications in pregnant women with antiphospholipid syndrome. ASA-sensitive pregnant women cannot benefit from the effects of ASA due to the possibility of severe or potentially life-threatening hypersensitivity reactions to ASA. ASA desensitization is a valuable and safe therapeutic option for these women, allowing them to start daily prophylaxis with ASA and prevent pregnancy complications. The authors discuss the recent advances in obstetric conditions preventable by ASA and the management of ASA hypersensitivity in pregnancy, including ASA desensitization. To encourage the implementation of ASA desensitization protocols in ASA-sensitive pregnant women, they also propose a practical approach for use in daily clinical practice. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-15T22:21:09Z 2021-04 2021-04-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/119316 |
url |
http://hdl.handle.net/10362/119316 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1010-660X PURE: 29781806 https://doi.org/10.3390/medicina57040390 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817545804338954240 |